News
AFFY
0.0009
NaN%
--
Weekly Report: what happened at AFFY last week (0908-0912)?
Weekly Report · 09/15 10:39
Weekly Report: what happened at AFFY last week (0901-0905)?
Weekly Report · 09/08 10:41
Weekly Report: what happened at AFFY last week (0825-0829)?
Weekly Report · 09/01 10:37
Weekly Report: what happened at AFFY last week (0818-0822)?
Weekly Report · 08/25 10:45
Weekly Report: what happened at AFFY last week (0811-0815)?
Weekly Report · 08/18 10:40
Weekly Report: what happened at AFFY last week (0804-0808)?
Weekly Report · 08/11 10:45
Weekly Report: what happened at AFFY last week (0728-0801)?
Weekly Report · 08/04 10:47
Weekly Report: what happened at AFFY last week (0721-0725)?
Weekly Report · 07/28 10:48
Weekly Report: what happened at AFFY last week (0714-0718)?
Weekly Report · 07/21 10:40
Weekly Report: what happened at AFFY last week (0707-0711)?
Weekly Report · 07/14 10:47
Weekly Report: what happened at AFFY last week (0630-0704)?
Weekly Report · 07/07 10:41
Weekly Report: what happened at AFFY last week (0623-0627)?
Weekly Report · 06/30 10:46
Weekly Report: what happened at AFFY last week (0616-0620)?
Weekly Report · 06/23 10:40
Weekly Report: what happened at AFFY last week (0609-0613)?
Weekly Report · 06/16 10:46
Weekly Report: what happened at AFFY last week (0602-0606)?
Weekly Report · 06/09 10:46
Weekly Report: what happened at AFFY last week (0526-0530)?
Weekly Report · 06/02 10:52
Weekly Report: what happened at AFFY last week (0519-0523)?
Weekly Report · 05/26 10:52
Weekly Report: what happened at AFFY last week (0512-0516)?
Weekly Report · 05/19 10:45
Weekly Report: what happened at AFFY last week (0505-0509)?
Weekly Report · 05/12 10:45
Weekly Report: what happened at AFFY last week (0428-0502)?
Weekly Report · 05/05 10:47
More
Webull provides a variety of real-time AFFY stock news. You can receive the latest news about Affymax through multiple platforms. This information may help you make smarter investment decisions.
About AFFY
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.